Alector Inc.
Clinical trials sponsored by Alector Inc., explained in plain language.
-
Alzheimer's drug AL002 safety trial ends early
Disease control TerminatedThis study was a long-term extension of an earlier trial, testing the safety and tolerability of AL002 in 197 people with early Alzheimer's disease. Participants received the drug by IV infusion. The trial was terminated, meaning it stopped before completion, so the full safety a…
Phase: PHASE2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Neurodegenerative drug study ends early after only 17 participants
Disease control TerminatedThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hope for genetic dementia: AL001 trial ends early
Disease control TerminatedThis phase 3 study tested a drug called AL001 in 119 people who carry a mutation in the progranulin gene, putting them at high risk for or already diagnosed with frontotemporal dementia. The goal was to see if AL001 could slow the worsening of memory, behavior, and language probl…
Phase: PHASE3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC